Literature DB >> 9434761

Telomerase activity in immortalized endothelial cells undergoing p53-mediated apoptosis.

S A Maxwell1, D Capp, S A Acosta.   

Abstract

Many cancer and immortal cells exhibit telomerase activity that stabilizes telomere lengths and may be involved in cell immortality and carcinogenesis. Downregulation of telomerase has been reported during differentiation of hematopoietic, melanoma, glioma, and myelocytic leukemia cells. Moreover, normal human mammary epithelial cells immortalized by a p53 mutant have been reported to exhibit activation of telomerase. However, no information is available about the activity of telomerase during p53-mediated apoptosis of immortalized cells. We investigated the activity of telomerase during p53-induced apoptosis of the immortalized endothelial cell line ECV-304. ECV-304 cells were induced into apoptosis by infection with a recombinant adenovirus that facilitated expression of high levels of wild-type p53. Telomerase activity was measured by a PCR-based telomeric repeat amplification protocol (TRAP). Telomerase activity was found to be unaffected by overexpression of p53 and apoptosis in immortalized endothelial cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9434761     DOI: 10.1006/bbrc.1997.7797

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  2 in total

1.  Telomerase activity and p53-dependent apoptosis in ovarian cancer cells.

Authors:  R Akeshima; J Kigawa; M Takahashi; T Oishi; Y Kanamori; H Itamochi; M Shimada; S Kamazawa; S Sato; N Terakawa
Journal:  Br J Cancer       Date:  2001-06-01       Impact factor: 7.640

2.  The isothiocyanate erucin abrogates telomerase in hepatocellular carcinoma cells in vitro and in an orthotopic xenograft tumour model of HCC.

Authors:  Corinna Herz; Anke Hertrampf; Stefan Zimmermann; Nadine Stetter; Meike Wagner; Claudia Kleinhans; Miriam Erlacher; Julia Schüler; Stefanie Platz; Sascha Rohn; Volker Mersch-Sundermann; Evelyn Lamy
Journal:  J Cell Mol Med       Date:  2014-09-25       Impact factor: 5.310

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.